Advertisement

Diabetologia

, Volume 38, Issue 3, pp 255–261 | Cite as

Acute onset of diabetic pathological changes in transgenic mice with human aldose reductase cDNA

  • T. Yamaoka
  • C. Nishimura
  • K. Yamashita
  • M. Itakura
  • T. Yamada
  • J. Fujimoto
  • Y. Kokai
Originals

Summary

To investigate the role of human aldose reductase (hAR) in the pathogenesis of diabetic complications, we generated transgenic mice carrying hAR cDNA driven by the murine MHC class I molecule promoter (hAR-Tg). Northern and Western blot analyses and immunoassay of hAR revealed that both hAR mRNA and the protein were expressed in all tissues tested. Thrombosis in renal vessels and fibrinous deposits in Bowman's capsule were observed in 6-week-old hAR-Tg mice fed a normal diet. Ingestion of a 30% glucose diet for 5 days caused sorbitol concentrations in the liver, kidney, and muscle of hAR-Tg mice to be elevated significantly. Seven-week-old hAR-Tg mice fed a 20% galactose diet for 7 days developed cataracts and occlusion of the retinochoroidal vessels, in addition to pathological changes in the kidney. Despite an elevated aldose reductase level in hAR-Tg mice and their intake of an aldose diet, no histopathological changes were found in other tissues, including the brain, lungs, heart, thymus, spleen, intestine, liver, muscle, spinal cord, or sciatic nerve. Results suggest that target organs of diabetic complications, such as the kidney, lens, and retina are sensitive to damage associated with a high level of AR expression, but other organs are not; the susceptibility of each organ to diabetic complications is determined by not only hAR but also other factors.

Key words

Transgenic mice aldose reductase diabetic angiopathies diabetic retinopathy diabetic nephropathies 

Abbreviations

hAR

Human aldose reductase

hAR-Tg

transgenic mice carrying hAR, cDNA

PCR

polymerase chain reaction

ARI

aldose reductase inhibitor

References

  1. 1.
    Frank RN (1991) On the pathogenesis of diabetic retinopathy: a 1990 update. Ophthalmol 98: 586–593Google Scholar
  2. 2.
    Raskin P, Rosenstock J (1987) Aldose reductase inhibitors and diabetic complications. Am J Med 83: 298–306CrossRefPubMedGoogle Scholar
  3. 3.
    Bays HE, Pfeifer MA (1988) Peripheral diabetic neuropathy. Med Clin North Am 72: 1439–1464PubMedGoogle Scholar
  4. 4.
    Harati Y (1987) Diabetic peripheral neuropathies. Ann Intern Med 107: 546–549PubMedGoogle Scholar
  5. 5.
    Greene DA, Lattimer SA, Sima AAF (1988) Perspectives in diabetes: are disturbances of sorbitol phosphoinositide, and Na+ -K+ -ATPase regulation involved in pathogenesis of diabetic neuropathy? Diabetes 37: 688–693PubMedGoogle Scholar
  6. 6.
    Cohen MP (1989) Nonenzymatic glycation and enhanced polyol pathway activity in the pathogenesis of diabetic neuropathy. Contrib Nephrol 73: 59–72PubMedGoogle Scholar
  7. 7.
    Cerami A, Stevens VJ, Monnier VM (1979) Role of nonenzymatic glycosylation in the development of the sequelae of diabetes mellitus. Metabolism 28[Suppl. 1]: 431–437PubMedGoogle Scholar
  8. 8.
    Brownlee M, Cerami A (1981) The biochemistry of the complications of diabetes mellitus. Ann Rev Biochem 50: 385–432CrossRefPubMedGoogle Scholar
  9. 9.
    Kennedy L, Baynes JW (1981) Nonenzymatic glycosylation and the chronic complications of diabetes: an overview. Diabetologia 26: 93–98Google Scholar
  10. 10.
    Akagi Y, Yajima Y, Kador PF, Kuwabara T, Kinoshita JH (1984) Localization of aldose reductase in the human eye. Diabetes 33: 562–566PubMedGoogle Scholar
  11. 11.
    Ludvigson MA, Sorenson RL (1980) Immunohistochemical localization of aldose reductase. II. Rat eye and kidney. Diabetes 29: 450–459PubMedGoogle Scholar
  12. 12.
    Akagi Y, Kador PF, Kuwabara T, Kinoshita JH (1983) Aldose reductase localization in human retinal mural cells. Invest Ophthalmol Vis Sci 24: 1516–1519PubMedGoogle Scholar
  13. 13.
    Ludvigson MA, Sorenson RL (1980) Immunohistochemical localization of aldose reductase. I. Enzyme purification and antibody preparation: localization in peripheral nerve, artery, and testis. Diabetes 29: 438–449PubMedGoogle Scholar
  14. 14.
    Nishimura C, Matsuura Y, Kokai Y et al. (1990) Cloning and expression of human aldose reductase. J Biol Chem 265: 9788–9792PubMedGoogle Scholar
  15. 15.
    Nishi M, Ishida Y, Honjo T (1988) Expression of functional interleukin-2 receptors in human light chain/Tac transgenic mice. Nature 331: 267–269PubMedGoogle Scholar
  16. 16.
    Ishida Y, Nishi M, Taguchi O et al. (1989) Effects of the deregulated expression of human interleukin-2 in transgenic mice. Int Immunol 1: 113–120PubMedGoogle Scholar
  17. 17.
    Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning: a laboratory manual. 2nd edn. Cold Spring Harbor Laboratory, New YorkGoogle Scholar
  18. 18.
    Hogan B, Costantini F, Lacy E (1986) Manipulating the mouse embryo: a laboratory manual. Cold Spring Harbor Laboratory, New YorkGoogle Scholar
  19. 19.
    Harlow E, Lane D (1988) Antibodies: a laboratory manual. Cold Spring Harbor Laboratory, New YorkGoogle Scholar
  20. 20.
    Morjano NA, Flynn TG (1989) Aldose reductase from human psoas muscle: purification, substrate specificity, immunological characterization, and effect of drugs and inhibitors. J Biol Chem 264: 2906–2911PubMedGoogle Scholar
  21. 21.
    Yamaoka T, Matsuura Y, Yamashita K, Tanimoto T, Nishimura C (1992) Site-directed mutagenesis of His-42, His-188, and Lys-263 of human aldose reductase. Biochem Biophys Res Commun 183: 327–333PubMedGoogle Scholar
  22. 22.
    Nishimura C, Furue M, Ito T, Omori Y, Tanimoto T (1993) Quantitative determination of human aldose reductase by enzyme-linked immunosorbent assay. Biochem Pharmacol 46: 21–28CrossRefPubMedGoogle Scholar
  23. 23.
    Bohren KM, Bullock B, Wermuth B, Gabbay KH (1989) The aldo-keto reductase superfamily: cDNAs and deduced amino acid sequences of human aldehyde and aldose reductases. J Biol Chem 264: 9547–9551PubMedGoogle Scholar
  24. 24.
    Pailhoux EA, Martinez A, Veyssiere GM, Jean CG (1990) Androgen-dependent protein from mouse vas deferens: cDNA cloning and protein homology with the aldo-keto reductase superfamily. J Biol Chem 265: 19932–19936PubMedGoogle Scholar
  25. 25.
    Ludvigson MA, Waites GMH, Hamilton DW (1982) Immunocytochemical evidence for the specific localization of aldose reductase in rat Sertoli cells. Biol Reprod 26: 311–317PubMedGoogle Scholar
  26. 26.
    van Heyningen R (1959) Formation of polyols by the lens of the rat with sugar cataract. Nature 184: 194–195Google Scholar
  27. 27.
    Robins SL, Cotran RS, Kumar V (1984) The kidney. In: Pathologic basis of disease. W. B. Saunders Co, Philadelphia, pp 1022–1025Google Scholar
  28. 28.
    Engerman, RL, Kern TS (1984) Experimental galactosemia produces diabetic-like retinopathy. Diabetes 33: 97–100PubMedGoogle Scholar
  29. 29.
    Dvornik D (1987) Aldose reductase inhibitors. In: Porte D (ed) Aldose reductase inhibition: an approach to the prevention of diabetic complications. Biomedical Information Corporation, New York, pp 221–323Google Scholar

Copyright information

© Springer-Verlag 1995

Authors and Affiliations

  • T. Yamaoka
    • 1
  • C. Nishimura
    • 2
  • K. Yamashita
    • 1
  • M. Itakura
    • 1
  • T. Yamada
    • 2
  • J. Fujimoto
    • 2
  • Y. Kokai
    • 2
  1. 1.Division of Endocrinology and Metabolism, Institute of Clinical MedicineUniversity of TsukubaTsukuba-CityJapan
  2. 2.Departments of Pediatric Pharmacology and PathologyNational Children's Medical Research CenterTokyoJapan

Personalised recommendations